Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Nearly all HIV-positive study participants achieved protective antibody levels after two doses of Heplisav-B.
A federal advisory panel has recommended a new vaccine against the virus specifically tailored to adults.
Beyond hepatitis A and C, taking a look at hepatitis B and D.
The FDA has once again rejected the California-based biotech’s request to approve Heplisav-B.
Heplisav, a new hepatitis B virus (HBV) vaccine being development by Dynavax Technologies Corporation, is both well-tolerated and effective
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.